Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (480) 480
index medicus (348) 348
bendamustine hydrochloride (300) 300
female (290) 290
male (290) 290
bendamustine (269) 269
middle aged (262) 262
aged (260) 260
oncology (247) 247
antineoplastic combined chemotherapy protocols - therapeutic use (245) 245
hematology (242) 242
rituximab (213) 213
nitrogen mustard compounds - administration & dosage (194) 194
adult (160) 160
treatment outcome (151) 151
bendamustine hydrochloride - administration & dosage (147) 147
leukemia, lymphocytic, chronic, b-cell - drug therapy (134) 134
aged, 80 and over (123) 123
chemotherapy (122) 122
nitrogen mustard compounds - therapeutic use (119) 119
nitrogen mustard compounds - adverse effects (115) 115
antineoplastic combined chemotherapy protocols - adverse effects (113) 113
antineoplastic agents (107) 107
antimitotic agents (104) 104
cancer (102) 102
lymphomas (102) 102
non-hodgkins-lymphoma (92) 92
care and treatment (85) 85
rituximab - administration & dosage (84) 84
plus rituximab (81) 81
antibodies, monoclonal, murine-derived - administration & dosage (79) 79
therapy (77) 77
antineoplastic agents - therapeutic use (73) 73
antineoplastic combined chemotherapy protocols - administration & dosage (72) 72
recurrence (72) 72
chronic lymphocytic-leukemia (68) 68
disease-free survival (67) 67
medicine & public health (67) 67
cyclophosphamide (65) 65
antineoplastic agents, alkylating - therapeutic use (64) 64
pharmacology & pharmacy (64) 64
trial (62) 62
bendamustine hydrochloride - adverse effects (59) 59
chronic lymphocytic leukemia (58) 58
drug administration schedule (57) 57
lymphoma, non-hodgkin - drug therapy (57) 57
multicenter (57) 57
retrospective studies (57) 57
lymphoma (56) 56
fludarabine (55) 55
antineoplastic agents - administration & dosage (54) 54
lymphoma, mantle-cell - drug therapy (54) 54
multiple myeloma - drug therapy (54) 54
leukemia (53) 53
bendamustine hydrochloride - therapeutic use (52) 52
drug therapy (51) 51
survival (48) 48
antineoplastic agents - adverse effects (47) 47
efficacy (47) 47
neoplasm staging (47) 47
analysis (46) 46
remission induction (46) 46
toxicity (46) 46
antineoplastic agents, alkylating - administration & dosage (45) 45
antineoplastic agents, alkylating - adverse effects (45) 45
bortezomib (45) 45
cyclophosphamide - administration & dosage (45) 45
multiple myeloma (45) 45
mantle cell (44) 44
prognosis (43) 43
combination (42) 42
mantle cell lymphoma (42) 42
1st-line treatment (41) 41
animals (40) 40
phase-ii multicenter (40) 40
clinical trials (39) 39
follow-up studies (39) 39
hematology, oncology and palliative medicine (39) 39
lymphoma, b-cell - drug therapy (39) 39
phase-ii (39) 39
dosage and administration (38) 38
indolent (37) 37
cll (36) 36
stem-cell transplantation (36) 36
lymphoma, follicular - drug therapy (35) 35
relapse (35) 35
hemic and lymphatic diseases (34) 34
indolent b-cell (34) 34
neoplasm recurrence, local - drug therapy (34) 34
patients (34) 34
salvage therapy (34) 34
in-vitro (33) 33
transplantation (33) 33
vidarabine - analogs & derivatives (33) 33
drug resistance, neoplasm (32) 32
leukemia, lymphocytic, chronic, b-cell - pathology (32) 32
phase-ii trial (32) 32
previously untreated patients (32) 32
research (32) 32
survival rate (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (500) 500
Japanese (12) 12
German (11) 11
Russian (3) 3
Spanish (2) 2
Chinese (1) 1
Czech (1) 1
French (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Synergistic anticancer efficacy of Bendamustine Hydrochloride loaded bioactive Hydroxyapatite nanoparticles: In-vitro, ex-vivo and in-vivo evaluation
by Thomas, Shindu C and Sharma, Harshita and Rawat, Purnima and Verma, Anita K and Leekha, Ankita and Kumar, Vijay and Tyagi, Aakriti and Gurjar, Bahadur S and Iqbal, Zeenat and Talegaonkar, Sushama
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Drug loaded Hydroxyapatite nanoparticles degrade to release Calcium ions (Ca ) and drug (D) inside the cell, which act synergistically to bring about tumor... 
Hydroxyapatite nanoparticles | Sustained delivery | Bendamustine Hydrochloride | Synergism | Cancer therapy | APOPTOSIS | MATERIALS SCIENCE, BIOMATERIALS | HUMAN PLASMA | DRUG-DELIVERY | CHEMISTRY, PHYSICAL | BIODISTRIBUTION | MECHANISMS | BIOPHYSICS | CISPLATIN | KINETICS | CALCIUM | INHIBITOR | CYTOTOXICITY | Nanoparticles - chemistry | Rats, Wistar | Apoptosis - drug effects | Humans | Drug Carriers - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Drug Delivery Systems | Bendamustine Hydrochloride - administration & dosage | Durapatite - administration & dosage | Durapatite - pharmacology | Antineoplastic Agents - pharmacology | Carcinoma, Ehrlich Tumor - pathology | Jurkat Cells | Rats | Carcinoma, Ehrlich Tumor - drug therapy | Durapatite - chemistry | Antineoplastic Agents - chemistry | Animals | Bendamustine Hydrochloride - pharmacology | Bendamustine Hydrochloride - chemistry | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | In Vitro Techniques | Nanoparticles | Antimitotic agents | Care and treatment | Antineoplastic agents | Cancer | Adsorption | Analysis | Precipitation (Meteorology)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Nanosized complexation assemblies housed inside reverse micelles churn out monocytic delivery cores for bendamustine hydrochloride
by Singh, Yuvraj and Singh, Pankaj K and Chandrashekhar, Anumandla and Meher, Jaya Gopal and Durga Rao Viswanadham, K.K and Pawar, Vivek K and Raval, Kavit and Sharma, Komal and Kumar, Animesh and Chourasia, Manish K
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 04/2017, Volume 113, pp. 198 - 210
We explore a plausible method of targeting bendamustine hydrochloride (BM) to circulatory monocytes by exploiting their intrinsic endocytic/phagocytic... 
Cell uptake | Bendamustine hydrochloride | DLS | Reverse micelle | Monocyte targeting | AOT | DRUG | APOPTOSIS | DYNAMIC LIGHT-SCATTERING | RECOGNITION | MACROPHAGES | CHITOSAN | BREAST-CANCER CELLS | NANOPARTICLES | PHARMACOLOGY & PHARMACY | RECEPTORS | Microscopy, Electron, Transmission | Phagocytosis - drug effects | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Endocytosis - drug effects | Humans | Antineoplastic Agents, Alkylating - pharmacology | Antineoplastic Agents, Alkylating - administration & dosage | Drug Carriers | Nanoparticles | Bendamustine Hydrochloride - administration & dosage | Bendamustine Hydrochloride - pharmacology | Micelles | Cell Cycle - drug effects | Cell Line, Transformed | Fluorescent Dyes | Antimitotic agents | Antineoplastic agents | Pharmaceutical industry | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
by Seymour, John F and Kipps, Thomas J and Eichhorst, Barbara and Hillmen, Peter and D’Rozario, James and Assouline, Sarit and Owen, Carolyn and Gerecitano, John and Robak, Tadeusz and De la Serna, Javier and Jaeger, Ulrich and Cartron, Guillaume and Montillo, Marco and Humerickhouse, Rod and Punnoose, Elizabeth A and Li, Yan and Boyer, Michelle and Humphrey, Kathryn and Mobasher, Mehrdad and Kater, Arnon P
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
by Eichhorst, Barbara, Dr and Fink, Anna-Maria, MD and Bahlo, Jasmin, PhD and Busch, Raymonde, Dipl Math and Kovacs, Gabor, MD and Maurer, Christian, MD and Lange, Elisabeth, MD and Köppler, Hubert, Prof and Kiehl, Michael, Prof and Sökler, Martin, MD and Schlag, Rudolf, MD and Vehling-Kaiser, Ursula, MD and Köchling, Georg, MD and Plöger, Christoph, MD and Gregor, Michael, MD and Plesner, Torben, MD and Trneny, Marek, Prof and Fischer, Kirsten, MD and Döhner, Harmut, Prof and Kneba, Michael, Prof and Wendtner, Clemens-Martin, Prof and Klapper, Wolfram, Prof and Kreuzer, Karl-Anton, Prof and Stilgenbauer, Stephan, Prof and Böttcher, Sebastian, MD and Hallek, Michael, Prof and Int Grp Investigators and German CLL Study Grp GCLLSG and German CLL Study Group (GCLLSG) and international group of investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 928 - 942
Summary Background Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FREE SURVIVAL | INITIAL THERAPY | IBRUTINIB | PROGRESSION-FREE | FRONTLINE FLUDARABINE | COMBINATION | PREVIOUSLY UNTREATED PATIENTS | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Survival Rate | Vidarabine - analogs & derivatives | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | International Agencies | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Aged, 80 and over | Adult | Female | Aged | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neoplasm Staging | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Epidemiology | Cyclophosphamide | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia
by Cervantes-Gomez, Fabiola and Lamothe, Betty and Woyach, Jennifer A and Wierda, William G and Keating, Michael J and Balakrishnan, Kumudha and Gandhi, Varsha
Clinical Cancer Research, ISSN 1078-0432, 08/2015, Volume 21, Issue 16, pp. 3705 - 3715
Purpose: Bruton's tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor pathway and is inhibited by ibrutinib due to covalent binding to the kinase... 
B-CELL RECEPTOR | TUMOR PROLIFERATION | BRUTONS TYROSINE KINASE | CLL | ONCOLOGY | BCL-2 INHIBITOR | INITIAL THERAPY | IN-VIVO | PCI-32765 | KINASE INHIBITOR IBRUTINIB | SINGLE-ARM | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Apoptosis - drug effects | Humans | Neoplastic Cells, Circulating - metabolism | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Purines - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Protein-Tyrosine Kinases - genetics | Female | bcl-X Protein - biosynthesis | Protein-Tyrosine Kinases - biosynthesis | B-Cell Activating Factor - biosynthesis | Neoplastic Cells, Circulating - drug effects | Pyrimidines - administration & dosage | Gene Expression Regulation, Leukemic - drug effects | Nitrophenols - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Pyrazoles - administration & dosage | B-Cell Activating Factor - genetics | Biphenyl Compounds - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Isoquinolines - administration & dosage | Proto-Oncogene Proteins c-bcl-2 - genetics | Sulfonamides - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
by Chanan-Khan, Asher, Prof and Cramer, Paula, MD and Demirkan, Fatih, MD and Fraser, Graeme, MD and Silva, Rodrigo Santucci, MD and Grosicki, Sebastian, Prof and Pristupa, Aleksander, MD and Janssens, Ann, MD and Mayer, Jiri, Prof and Bartlett, Nancy L, Prof and Dilhuydy, Marie-Sarah, MD and Pylypenko, Halyna, MD and Loscertales, Javier, MD and Avigdor, Abraham, MD and Rule, Simon, Prof and Villa, Diego, MD and Samoilova, Olga, MD and Panagiotidis, Panagiots, Prof and Goy, Andre, MD and Mato, Anthony, MD and Pavlovsky, Miguel A, MD and Karlsson, Claes, MD and Mahler, Michelle, MD and Salman, Mariya, PhD and Sun, Steven, PhD and Phelps, Charles, MS and Balasubramanian, Sriram, PhD and Howes, Angela, PhD and Hallek, Michael, MD and HELIOS Investigators and HELIOS investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 200 - 211
Summary Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is... 
Hematology, Oncology and Palliative Medicine | CLL | BRUTON TYROSINE KINASE | ONCOLOGY | MANTLE CELL LYMPHOMA | INHIBITOR IBRUTINIB | CYCLOPHOSPHAMIDE | DISEASE | BTK | FLUDARABINE | Atrial Fibrillation - chemically induced | Nausea - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bendamustine Hydrochloride - administration & dosage | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Pyrazoles - adverse effects | Double-Blind Method | Pyrimidines - administration & dosage | Anemia - chemically induced | Thrombocytopenia - chemically induced | Disease Progression | Rituximab - administration & dosage | Disease-Free Survival | Retreatment | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Pyrimidines - adverse effects | Aged | Hemorrhage - chemically induced | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antimitotic agents | Tyrosine | Prevention | Lymphomas | Comparative analysis | Antineoplastic agents | Cancer | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
by Zelenetz, Andrew D, Prof and Barrientos, Jacqueline C, MD and Brown, Jennifer R, MD and Coiffier, Bertrand, Prof and Delgado, Julio, MD and Egyed, Miklós, Prof and Ghia, Paolo, MD and Illés, Árpád, Prof and Jurczak, Wojciech, MD and Marlton, Paula, MBBS and Montillo, Marco, MD and Morschhauser, Franck, Prof and Pristupa, Alexander S, MD and Robak, Tadeusz, Prof and Sharman, Jeff P, MD and Simpson, David, MBChB and Smolej, Lukáš, MD and Tausch, Eugen, MD and Adewoye, Adeboye H, MD and Dreiling, Lyndah K, MD and Kim, Yeonhee, PhD and Stilgenbauer, Stephan, Prof and Hillmen, Peter, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Summary Background Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia.... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | IBRUTINIB | DIAGNOSIS | ONCOLOGY | Prognosis | Double-Blind Method | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Quinazolinones - administration & dosage | Male | Survival Rate | Purines - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Neoplasm Recurrence, Local - pathology | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Neoplasm Staging | Drug Resistance, Neoplasm - drug effects | Clinical trials | Relapse | Care and treatment | Diseases | Bendamustine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
by Rummel, Mathias, Prof and Kaiser, Ulrich, Prof and Balser, Christina, MD and Stauch, Martina, MD and Brugger, Wolfram, Prof and Welslau, Manfred, MD and Niederle, Norbert, Prof and Losem, Christoph, MD and Boeck, Hans-Peter, MD and Weidmann, Eckhart, Prof and von Gruenhagen, Ulrich, MD and Mueller, Lothar, MD and Sandherr, Michael, MD and Hahn, Lars, MD and Vereshchagina, Julia, MD and Kauff, Frank, PhD and Blau, Wolfgang, MD and Hinke, Axel, PhD and Barth, Juergen, Pharmacist and Study Grp Indolent Lymphomas StiL and Study Group Indolent Lymphomas
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Summary Background Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | FOLLICULAR LYMPHOMA | LOW-GRADE | ONCOLOGY | CHEMOTHERAPY | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Vidarabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Male | Survival Rate | Treatment Outcome | Vidarabine - analogs & derivatives | Infection - chemically induced | Rituximab - administration & dosage | Disease-Free Survival | Retreatment | Bendamustine Hydrochloride - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Aged | Vidarabine - administration & dosage | Rituximab - adverse effects | Antimitotic agents | Care and treatment | Chemotherapy | Lymphomas | Product development | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Mantle cell lymphoma
by Cheah, Chan Yoon and Seymour, John F and Wang, Michael L
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1256 - 1269
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first... 
PHASE-II TRIAL | SINGLE-AGENT TEMSIROLIMUS | ONCOLOGY | PROGRESSION-FREE SURVIVAL | BENDAMUSTINE PLUS RITUXIMAB | CANCER-TREATMENT-GROUP | NON-HODGKIN-LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | CHIMERIC ANTIGEN RECEPTOR | COOPERATIVE-ONCOLOGY-GROUP | STUDY-GROUP GLSG | Lymphoma, Mantle-Cell - surgery | Prognosis | Humans | Gene Expression Regulation, Neoplastic | Lymphoma, Mantle-Cell - pathology | Induction Chemotherapy | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Bortezomib - pharmacology | Thalidomide - pharmacology | Lymphoma, Mantle-Cell - diagnosis | Thalidomide - analogs & derivatives | Bendamustine Hydrochloride - administration & dosage | Maintenance Chemotherapy | Lymphoma, Mantle-Cell - metabolism | Molecular Targeted Therapy - methods | Pyrazoles - pharmacology | Drug Administration Schedule | Risk Factors | Hematopoietic Stem Cell Transplantation | Lymphoma, Mantle-Cell - drug therapy | Pyrimidines - pharmacology | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
by Cramer, Paula and von Tresckow, Julia and Bahlo, Jasmin and Robrecht, Sandra and Langerbeins, Petra and Al-Sawaf, Othman and Engelke, Anja and Fink, Anna-Maria and Fischer, Kirsten and Tausch, Eugen and Seiler, Till and Fischer von Weikersthal, Ludwig and Hebart, Holger and Kreuzer, Karl-Anton and Böttcher, Sebastian and Ritgen, Matthias and Kneba, Michael and Wendtner, Clemens-Martin and Stilgenbauer, Stephan and Eichhorst, Barbara and Hallek, Michael
The Lancet Oncology, ISSN 1470-2045, 09/2018, Volume 19, Issue 9, pp. 1215 - 1228
Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity... 
IN-VITRO | CLL | ONCOLOGY | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | IBRUTINIB | II TRIAL | MINIMAL RESIDUAL DISEASE | FLUDARABINE | PROGRESSION | Antibodies, Monoclonal, Humanized - adverse effects | Prospective Studies | Drug Administration Schedule | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Germany | Sulfonamides - administration & dosage | Antimitotic agents | Product development | Antineoplastic agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
by Sehn, Laurie H, Dr and Chua, Neil, MD and Mayer, Jiri, Prof and Dueck, Gregg, MD and Trněný, Marek, Prof and Bouabdallah, Kamal, MD and Fowler, Nathan, MD and Delwail, Vincent, MD and Press, Oliver, Prof and Salles, Gilles, MD and Gribben, John, Prof and Lennard, Anne, MBBS and Lugtenburg, Pieternella J, MD and Dimier, Natalie, MSc and Wassner-Fritsch, Elisabeth, PharmD and Fingerle-Rowson, Günter, MD and Cheson, Bruce D, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1081 - 1093
Summary Background Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituximab-based treatment have few treatment... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | B-CELL LYMPHOMA | II MULTICENTER | THERAPY | ONCOLOGY | FREE SURVIVAL | CYCLOPHOSPHAMIDE | MANTLE CELL | ANTIBODY | FOLLICULAR LYMPHOMA | GA101 | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Aged | Neoplasm Staging | Drug Resistance, Neoplasm - drug effects | Lymphoma, Non-Hodgkin - drug therapy | Antimitotic agents | Monoclonal antibodies | Care and treatment | Lymphomas | Product development | Antineoplastic agents | Analysis | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study
by Santoro, Armando and Mazza, Rita and Pulsoni, Alessandro and Re, Alessandro and Bonfichi, Maurizio and Zilioli, Vittorio Ruggero and Salvi, Flavia and Merli, Francesco and Anastasia, Antonella and Luminari, Stefano and Annechini, Giorgia and Gotti, Manuel and Peli, Annalisa and Liberati, Anna Marina and Di Renzo, Nicola and Castagna, Luca and Giordano, Laura and Carlo-Stella, Carmelo
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3293 - 3299
Purpose This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy... 
EFFICACY | ONCOLOGY | SAFETY | DISEASE | BRENTUXIMAB VEDOTIN | EXPERIENCE | BLOCKADE | MELPHALAN | PROGRAM | Antigens, CD34 - metabolism | Prospective Studies | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Young Adult | Bendamustine Hydrochloride - administration & dosage | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Deoxycytidine - adverse effects | Female |